Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00736450|
Recruitment Status : Terminated (Manufacturer is no longer making the drug.)
First Posted : August 15, 2008
Results First Posted : August 31, 2018
Last Update Posted : August 31, 2018
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Biological: oblimersen sodium
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Genetic: microarray analysis
Other: immunohistochemistry staining method
Genetic: gene expression analysis
Genetic: cytogenetic analysis
Of the 37 subjects consented, 19 were Not ABC gene type positive so were removed from the study.
Of the 18 remaining eligible, 4 patients opted for standard of care and withdrew from the study.
13 subjects had microarray analysis conducted with tissue.